Onderneming Clarus Therapeutics Holdings, Inc.
Aandelen
CRXT
US18271L1070
Farmaceutische producten
Vakgebied
Aantal werknemers: 16
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Dudley
FOU | Founder | 69 | 01-01-04 |
Jay Newmark
CTO | Chief Tech/Sci/R&D Officer | - | - |
Kara Stancell
IRC | Investor Relations Contact | - | - |
Sales & Marketing | - | 01-03-20 | |
Corporate Officer/Principal | - | 17-01-22 | |
James Holloway
PRN | Corporate Officer/Principal | - | - |
Lawrence Perkins
PRN | Corporate Officer/Principal | 47 | - |
Mike Cleveland
SAM | Sales & Marketing | - | 01-02-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Dudley
FOU | Founder | 69 | 01-01-04 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 52 020 731 | 50 674 645 ( 97,41 %) | 0 | 97,41 % |
Bedrijfsgegevens
Clarus Therapeutics Holdings, Inc.
355 South Grand Avenue Suite 1450
90071, Los Angeles
+
http://clarustherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+54,61% | 815 mld. | |
+44,25% | 654 mld. | |
-6,33% | 354 mld. | |
+20,62% | 337 mld. | |
+10,44% | 302 mld. | |
+18,45% | 247 mld. | |
+2,09% | 229 mld. | |
+13,03% | 219 mld. | |
+8,61% | 171 mld. |